Landmark Lawsuit Filed Against SEC to Protect Future Whistleblowers

June 05, 2020

Stiefel Laboratories Inc., Charles W. Stiefel

Trading and Pricing


Defendants: Stiefel Laboratories Inc.
Charles W. Stiefel

Company and its former Chairman/CEO consented to entry of final judgment in case alleging that they conducted share buybacks (mostly from employees) without disclosing negotiations with GlaxoSmithKline PLC that resulted in an acquisition at a share price more than four times higher than the buyback price.

Named one of the top whistleblower practices/attorneys in the country by The New York Times, Wall Street Journal and NPR
Thank you for submitting some email to us.